Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29957183 | 0.98 | BACE1 (0.30) | HIF1ABACE1 | |
| SCHEMBL16579802 | 0.82 | BACE1 (0.33) | BACE1 | |
| SCHEMBL1518260 | 0.77 | HRH3 (0.38) | — | |
| Hydrochloric Acid SCHEMBL29952193 | 0.76 | BACE1 (0.30) | BACE1 | |
| SCHEMBL12559910 | 0.76 | HRH3 (0.40) | — | |
| SCHEMBL5924367 | 0.76 | NOS2 (0.46) | BACE1 | |
| SCHEMBL12559895 | 0.75 | ALDH1A1 (0.41) | — | |
| Hydrochloric Acid SCHEMBL1518158 | 0.74 | HRH3 (0.39) | — | |
| SCHEMBL474833 | 0.74 | KCNH2 (0.46) | BACE1 | |
| SCHEMBL12855201 | 0.74 | PAOX (0.34) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| EP-2558577-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011127933-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2011-10-20 | — | — | WO | disclosed |
| US-20080181923-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE DERIVATIVES | NORTH CAROLINA STATE UNIVERSITY | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080181923-A1 | INHIBITION OF BACTERIAL BIOFILMS WITH IMIDAZOLE DERIVATIVES | O60361, TFPI, BLVRB | HIF1A 3700/4885BACE1 3382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.